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activity of tigecycline against recent (2006) bacterial iso-
lates across Australia.
Methods: Non-duplicate strains were consecutively col-
lected from ﬁve medical centres in 5 states using isolates
from bacteraemia (n = 253), pneumonia (n = 146), compli-
cated skin and skin structure infections (n = 264), and
other infections (n = 269). All isolates were tested against
tigecycline using validated commercial reference broth
microdilution panels (TREK Diagnostics), with concurrent
quality controls and CLSI (M100-S18) interpretations for
comparison agents. Tigecycline breakpoints published by the
US-FDA were applied for each indicated species or genus
group.
Results: A total of 932 (268 Gram-negative and 664
Gram-positive) isolates were processed. Tigecycline was
highly active against the top 10 non-pseudomonal pathogens
which comprised 88% of all tested isolates. Tigecycline
MIC90 results ranged from ≤0.12 to 1mg/L, highest for
Klebsiella spp. and Proteae (data not shown). At US-FDA
published breakpoints, tigecycline exhibited complete inhi-
bition of indicated species except for a single strain of E.
cloacae (MIC, 4mg/L). Over 28% of Staphylococcus aureus
were oxacillin-resistant, and one Enterococcus faecium
was vancomycin-resistant. Tigecycline was highly effective
against these strains.
Conclusions: Tigecycline has potent activity against all
the common pathogens isolated in 2006 from Australian
patients, including those resistant to other drug classes.
Documented acquired resistance was rare among indicated
pathogens, however, Pseudomonas remains refractory to
potential tigecycline therapy.
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Objectives: Worldwide the prevalence of MDR Enter-
obacteriaceae are increasing, including ESBLs, AmpC,
ﬂuoroquinolone and carbapenem resistant strains. The
T.E.S.T. program determined the in vitro activity of tigecy-
cline compared to amoxicillin-clavulanic acid, piperacillin-
tazobactam, levoﬂoxacin, ceftriaxone, cefepime, ampi-
cillin, amikacin, minocycline, ceftazidime and imipenem
against Enterobacteriaceae species collected from hospi-
tals in Asia/Paciﬁc Rim 2004—2007. This study evaluated
the activity of tigecycline against multi-resistant microor-
ganisms associated with nosocomial infections.
Methods: A total of 2778 clinical isolates were identiﬁed
to the species level at each site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentration (MICs) were
determined by each site using supplied broth microdilution
panels and interpreted according to CLSI guidelines. Tigecy-
cline breakpoint is deﬁned as susceptible MICs ≤2mcg/mL
Results: The table illustrates the %S and MIC90 of tigecy-
cline to MDR pathogens
Conclusions: Multi-drug resistance is common in health
care acquired pathogens. The presented data indicate that
tigecycline is highly potent against nosocomial pathogens
including MDR isolates.
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Objectives: Tigecycline (TIG) is a new glycylcycline with
enhanced activity against many multidrug resistant (MDR)
pathogens including ESBL and AmpC producing Enterobacte-
riaceae, methicillin-resistant S. aureus (MRSA), carbapenem
resistant Acinetobacter and ﬂuoroquinolone resistant gram-
negative rods. The TEST study evaluated the activity of TIG
and comparators to pathogens in Canada 2004—2007.
Methods: A total of 1675 pathogens were collected from 8
participating sites in Canada from 2004—2007. Isolates were
identiﬁed to the species level and CLSI speciﬁed MICs were
performed at each site. CLSI or FDA breakpoints were used,
where applicable, to determine % susceptibility
Results: Tigecycline MICs are recorded in the table below
Conclusions: Tigecycline showed excellent in vitro activ-
ity against a diverse collection of pathogens isolated in
Canada between 2004—2007. MIC90 values of 0.5mcg/ml
against most Enterobacteriaceae including ESBL and MIC90
of ≤0.12mcg/ml against gram-positive pathogens document
the in vitro potency of tigecycline, a new glycylcycline.
doi:10.1016/j.ijid.2008.05.1085
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Aim: To assess the antimicrobial resistance patern in
pathogens responsible for urinary tract infections in noso-
comial patients over a period of one year.
Material and Method: From January 2006 to Decem-
ber 2006, 3665 urine cultures from nosocomial patients
were collected. All positive cultures with a colony count
≥105CFU/ml for Gram-positive and Gram-negative bacte-
ria and ≥103CFU/ml for Candida species were selected for
the analysis. Duplicate isolates were not considered
Results: Among the 757 positive cultures n = 135 belonged
to I.C.U., n = 58 to Surgical Dept, n = 347 to Internal Medicine
Dept and n = 217 to Outpatien Dept. Among the 757 pos-
itive cultures n = 523 belonged to female and n = 234 to
